ASH Meeting on Hematologic Malignancies

ASH Meeting on Hematologic Malignancies

Coverage of ASH’s newest clinical meeting, featuring top experts in hematologic malignancies discussing the latest developments in clinical care and answering challenging patient care questions

TP53 Mutation Associated With Poor, But Varied, Outcomes in Myelodysplastic Syndromes

The TP53 mutation, a common molecular abnormality in myeloid malignancies such as myelodysplastic syndromes (MDS), is associated with poor outcomes; however, it is unclear...

Shared-Care Model of Post-Consolidation Care Reduces Travel Burden for AML Patients

In Canada, investigators have been evaluating a shared-care model for acute myeloid leukemia (AML) post-consolidation supportive therapy. The collaborative program permits patients to visit...

Ibrutinib + Bendamustine/Rituximab in Patients with Previously Treated CLL/SLL

The combination of ibrutinib and bendamustine/rituximab (BR) was well-tolerated and did not significantly affect the safety profile of BR in patients with previously treated...

Microtransplantation: A Better Option for AML Patients Without an HLA-Identical Donor?

The optimal therapy for patients with intermediate-risk acute myeloid leukemia (AML) in first complete remission is uncertain. Microtransplantation, the practice of infusing patients with...

Daratumumab Has Favorable Safety Profile in Relapsed/Refractory Multiple Myeloma Patients

For relapsed/refractory multiple myeloma (MM) patients treated with the anti-CD38 monoclonal antibody daratumumab, management of infusion-related reactions (IRRs) required temporary slowing or stopping of...

Researchers Identify Markers of Relapse in Post-Transplant Multiple Myeloma Patients

Results from an analysis presented at the 2015 ASH Meeting on Hematologic Malignancies confirm that T-cell exhaustion and senescence (occurring when T cells are...

HIV-Associated Lymphoma: Examining Treatment Patterns and Survival in the Antiretroviral Era

As use of antiretroviral therapy has increased, the incidence of Hodgkin lymphoma (HL) among HIV-positive patients has fallen, though it has not disappeared. For...

Is the Combo of Abbreviated Chemo Plus Radiation Therapy a Viable Option for DLBCL...

The National Comprehensive Cancer Network’s guidelines for the management of non-bulky diffuse large B-cell lymphoma (DLBCL) recommend that, for patients with early-stage disease, shortening...
You Make the Call

From ASH Meeting on Hematologic Malignancies: What would you recommend for a woman with...

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...

The Inaugural ASH Meeting on Hematologic Malignancies: A Discussion With the Co-Chairs

New clinical and biologic data within lymphoid and myeloid malignancies, including newly completed clinical trials, novel drugs, and insight into the genetic basis of these varied diseases is coming so fast and...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.